SCHEMBL5746671

SCHEMBL5746671

CN(C(=O)OC(C)(C)C)C(Cc1ccc(O)cc1)C(=O)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 2/20 0.50
ME1 P48163 2/20 0.50
ME3 Q16798 2/20 0.50
P2RX7 Q99572 1/20 0.46
POLB P06746 2/20 0.43
ADORA1 P30542 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5746665 1.00 ME2 (0.50) ME2ME1ME3P2RX7POLB
SCHEMBL5773095 0.91 SMN1; SMN2 (0.49) ME2ME1ME3P2RX7ADORA1
SCHEMBL5745397 0.91 SMN1; SMN2 (0.49) ME2ME1ME3P2RX7ADORA1
SCHEMBL5744099 0.90 ADORA1 (0.52) ME2ME1ME3P2RX7ADORA1
SCHEMBL5746587 0.90 P2RX7 (0.46) ME2ME1ME3P2RX7ADORA1
SCHEMBL5747764 0.90 ADORA1 (0.46) ME2ME1ME3P2RX7ADORA1
SCHEMBL5744094 0.90 ADORA1 (0.52) ME2ME1ME3P2RX7ADORA1
SCHEMBL5747758 0.90 ADORA1 (0.46) ME2ME1ME3P2RX7ADORA1
SCHEMBL5746583 0.90 P2RX7 (0.46) ME2ME1ME3P2RX7ADORA1
SCHEMBL5746972 0.90 MAPT (0.51) P2RX7ADORA1L3MBTL1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487449-A4 TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS KING PHARMACEUTICALS RES & DEV (US) 2006-08-23 EP claimed
US-7094895-B2 Tyrosyl derivatives and their use as P2X7 receptor modulators KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-08-22 US claimed
EP-1487449-A1 TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS King Pharmaceuticals Research and Development Inc. (US) 2004-12-22 EP claimed
US-20030181452-A1 Tyrosyl derivatives and their use as P2X7 receptor modulators CREDIT SUISSE AG 2003-09-25 US claimed
WO-2003059353-A1 TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2003-07-24 WO claimed
US-7094895-B2 Tyrosyl derivatives and their use as P2X7 receptor modulators KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-08-22 US disclosed
US-20030181452-A1 Tyrosyl derivatives and their use as P2X7 receptor modulators CREDIT SUISSE AG 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181452-A1 Tyrosyl derivatives and their use as P2X7 receptor modulators P2RX7, P2RX3, P2RX5 ME2 2238/4885ME1 4327/4885ME3 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.